The chaotic tariff situation is forcing pharma companies to prepare for multiple outcomes. While supply chain interruptions ...

Ferring Pharmaceuticals announced strong performance results for 2024, with one part of the announcement standing out as ...

Approval of penpulimab-kcqx marks the company’s US regulatory debut and introduces a new immunotherapy option for advanced ...

As the tariff situation continues to unfold in unexpected ways, the pharma industry must prepare for multiple eventualities.

The submission is backed by clinical data from over 2,100 patients, including two pivotal Phase III trials in patients ...

While supply chain interruptions are a strong possibility, the tariffs also provide the industry with a chance to improve ...

The simplified requirements for Camzyos are expected to ease prior contraindications, thereby simplifying treatment and ...

Results from the dual Phase III TRIUMpH trials demonstrated the statistical superiority of tegoprazan over lansoprazole in ...

CMS’ draft guidance on real-world data study protocols marks a significant move toward transparency and rigor in Medicare ...

In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with ...

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics ...

Pooja Lal, VP of strategy and commercial content at Veeva Systems, spoke with Pharmaceutical Executive about some of the ways ...